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Abstract
Background: Prior studies have demonstrated an increase in Clostridium difficile infection (CDI) incidence in the
United States (U.S.) in recent years, but trends among different age groups have not been evaluated. This study
describes national CDI incidence by age group over a 10-year period and mortality and hospital length of stay
(LOS) among patients with CDI.
Methods: This was a retrospective analysis of the U.S. National Hospital Discharge Surveys from 2001 to 2010.
Eligible patients with an ICD-9-CM discharge diagnosis code for CDI (008.45) were stratified by age: <18 years
(pediatrics), 18–64 years (adults), and ≥65 years (elderly adults). Data weights were used to derive national
estimates. CDI incidence was calculated as CDI discharges/1000 total discharges. Mortality and LOS were compared
between age groups using chi-square or Wilcoxon rank sum tests.
Results: These data represent 2.3 million hospital discharges for CDI over the study period. CDI incidence was
highest among elderly adults (11.6 CDI discharges/1000 total discharges), followed by adults (3.5 CDI discharges/
1000 total discharges) and pediatrics (1.2 CDI discharges/1000 total discharges). The elderly also had higher rates of
mortality (8.8%) compared to adults (3.1%) and pediatrics (1.4%) (p < 0.0001). In addition, median hospital LOS was
highest in the elderly (8 days) compared to adults (7 days) and pediatrics (6 days) (p < 0.0001).
Conclusions: CDI incidence among patients hospitalized in U.S. hospitals differed based on age group between
2001 and 2010. CDI incidence, mortality, and hospital LOS were highest in the elderly adult population.
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Background
Clostridium difficile is the most prevalent pathogen
among healthcare-associated infections and recognized by
the Centers of Disease Control and Prevention (CDC) as
one of the top three urgent threats to public health [1, 2].
C. difficile infection (CDI) often presents as diarrhea, but
can result in more severe clinical manifestations like toxic
megacolon, intestinal perforation, and sepsis. Additionally,
CDI can result in death (approximately 29,000 deaths in
2011) [3], prolonged patient hospital stays [4–6], and a
marked increase in the economic burden on the health-
care system with mean attributable costs ranging from
$8,911 to $30,049 per patient [7].
CDI incidence nearly doubled in United States (U.S.)
community hospitals between 2001 and 2010 [8]. A
similar report by the Agency for Healthcare Research
and Quality (AHRQ) estimated that the number of hos-
pitalizations due to CDI in the U.S. increased almost
four times from 1993 to 2009 with the majority of cases
affecting individuals 65 and older [9]. Prior studies have
affirmed that CDI disproportionately affects the elderly,
likely due to immunosuppression from advanced age or
chronic comorbidities, more health care exposures, and
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greater antibiotic use [10, 11]. Despite this, it is un-
known if incidence trends differ among age groups [3,
12]. Furthermore, trends in CDI health outcomes have
not been explored by age group.
The objectives of this study were to: 1) identify na-
tional CDI incidence trends by age group and 2) de-
scribe mortality and hospital length of stay (LOS) among
CDI patients by age group over a 10-year period.
Methods
This study utilized data from the CDC’s National Hos-
pital Discharge Surveys (NHDS) from 2001 to 2010. The
NHDS survey design and variable definitions have been
described previously [13]. Several prior infectious dis-
eases epidemiological studies, specifically evaluating
healthcare-associated infections, have utilized NHDS
data [8, 14, 15]. The UT Health Science Center San
Antonio Institutional Review Board waived formal ethics
approval and patient consent, as these data are publically
available and do not contain any patient identifiers.
This was a retrospective analysis of patients discharged
from U.S. hospitals from 2001 to 2010. Patients were in-
cluded if they had any (principal or secondary) Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) discharge diagnosis code for
CDI (008.45). The cohort was categorized into three age
groups: pediatrics (<18 years), adults (18–64 years), and
elderly adults (≥65 years).
Baseline patient demographics, as provided by the
NHDS variable categories, were summarized using me-
dian (interquartile range) for continuous variables and
counts (percentages) for categorical variables. Annual
CDI incidence rates were calculated between 2001 and
2010 using CDI discharges in each age group as the nu-
merator and total discharges in each age group as the
denominator. Data weights were applied to derive na-
tional estimates. Patient mortality represented all-cause,
in-hospital mortality and was identified by the “discharge
status” variable of the NHDS. Hospital LOS was identi-
fied using the “days of care” variable of the NHDS.
CDI incidence was compared by age group using the
z-score. Patient baseline characteristics, mortality, and
hospital LOS were compared by age group using appro-
priate bivariable statistics (chi-square test for categorical
variables and Wilcoxon rank sum test for continuous




Approximately 2.3 million CDI discharges over the study
period were included for analysis. Table 1 describes the
patients’ baseline demographics and hospital, payment,
and admissions characteristics. Of these patients, 67.5%
were elderly adults, 28.9% were adults, and 3.6% were
pediatrics. The patient population was predominately fe-
male (58.7%) and White (85.6%), with a median (IQR) age
of 74 (59–83) years. The median age for each group was
as follows: pediatrics (6 years), adults (53 years), and eld-
erly adults (80 years). Adult, elderly adult, and pediatric
patients with CDI significantly differed with respect to pa-
tient sex, race, hospital size and ownership, principal pay-
ment source, and admission type and source (p < 0.0001
for all) (Table 1). The principal payment source was Medi-
care for 67% of patient discharges, as expected by the high
proportion of elderly adult discharges in the study popula-
tion. The primary admission source was through the
emergency room for adults (60.3%) and elderly adults
(59.8%); however; pediatric patients were more likely to be
admitted by referral (39.2%).
CDI incidence by age group
Overall, CDI incidence significantly differed among age
groups (p < 0.0001) (Table 2). CDI incidence was higher
for elderly adults (11.6 CDI discharges/1000 total dis-
charges), compared to adults (3.5 CDI discharges/1000
total discharges) and pediatric populations (1.2 CDI dis-
charges/1000 total discharges). Elderly adults experi-
enced the greatest change in CDI incidence over the
study period (from 7.2 CDI discharges/1000 elderly adult
discharges in 2001 to 13.7 CDI discharges/1000 elderly
adult discharges in 2010) (Fig. 1). Among adults, CDI in-
cidence increased over the study period, from 2.4 CDI/
1000 adult discharges in 2001 to 4.3 CDI discharges/
1000 adult discharges in 2010. CDI remained relatively
unchanged among pediatrics over the study period (1.2
CDI/1000 pediatric discharges in 2001 and 2010).
Mortality and hospital LOS among patients with CDI by
age group
The overall all-cause, in-hospital mortality was 6.9% and
the median (IQR) hospital LOS was 8 (5–14) days. Mor-
tality and hospital LOS significantly differed by age
group (p < 0.0001 for each comparison). Mortality was
higher for elderly adults (8.8%) as compared to adult
(6.9%) and pediatric populations (3.1%) (p < 0.0001).
Among those patients with CDI who died, the most
common co-mortalities were septicemia (ICD-9-CM
code 038.X; 35.7%), acute renal failure (ICD-9-CM code
584.X; 31.8%), pneumonia (ICD-9-CM codes 480–
486.XX; 22.3%), and urinary tract infection (ICD-9-CM
codes 599.0; 18.8%). Similar to mortality, median hos-
pital LOS was longest for elderly adults (8 days),
followed by adults (7 days), and pediatrics (6 days) (p <
0.0001). There were no differences between male and fe-
male elderly CDI patients for mortality (8.8% for both
sexes) or median hospital LOS (8 days for both sexes).
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Discussion
Prior national epidemiological investigations demon-
strated considerable increases in CDI incidence over the
last decade [3, 15, 16]; however, this is the first study to
document the national burden of CDI longitudinally
among different age groups. This report identified a dis-
proportionate rise in CDI incidence among elderly adults,
with an estimated 61% rate of increase from 2001 to 2010.
Notably, elderly adults also suffered significantly higher
all-cause, in-hospital mortality and increased hospital LOS
compared to adult and pediatric patients.










Age (years), median (IQR) 74 (59–83) 80 (74-85) 52 (43-59) 5 (2–11) <0.0001
Female sex 58.7% 61.5% 54.4% 39.4% <0.0001
Race
White 85.6% 89.6% 77.2% 78.7% <0.0001
Black 10.1% 7.0% 16.7% 14.8%
Other 4.3% 3.4% 6.1% 6.5%
Hospital size
6–99 beds 19.4% 22.6% 13.7% 5.6% <0.0001
100–199 beds 21.1% 21.6% 20.4% 19.1%
200–299 beds 24.3% 24.8% 21.6% 36.1%
300–499 beds 22.7% 20.7% 27.1% 25.1%
500+ beds 12.5% 10.3% 17.2% 14.1%
Hospital ownership
Proprietary 11.7% 13.5% 8.2% 5.7% <0.0001
Government 8.6% 6.8% 12.9% 8.0%
Nonprofit 79.7% 79.7% 78.9% 86.3%
Principal payment source
Medicare 67.0% 88.3% 25.9% 0.0% <0.0001
Medicaid 8.1% 1.3% 18.7% 50.9%
Private 21.4% 9.2% 47.1% 43.1%
Self-pay 1.6% 0.4% 4.6% 0.1%
Other 1.9% 0.8% 3.7% 5.9%
Admission type
Emergency 64.9% 66.4% 64.0% 41.5% <0.0001
Urgent 21.5% 19.9% 24.1% 33.4%
Elective 13.4% 13.7% 11.9% 20.6%
Newborn 0.2% 0.0% 0.0% 4.5%
Admission source
Emergency room 59.3% 59.8% 60.3% 37.6% <0.0001
Transfer 15.1% 18.0% 8.8% 8.6%
Referral 18.1% 15.7% 21.6% 39.2%
Other 7.5% 6.5% 9.3% 14.6%
IQR Interquartile range
*P-values reflect comparisons between elderly adult, adult, and pediatric CDI populations
Table 2 CDI incidence and health outcomes by age group
Outcome Overall Elderly Adults Pediatrics P-value
CDI cases 2,279,004 1,538,933 657,513 82,558 –
CDI incidencea 4.5 11.6 3.5 1.2 <0.0001
Mortality 6.9% 8.8% 3.1% 1.4% <0.0001
Hospital LOS 8 (4–14) 8 (5–14) 7 (4–14) 6 (3–16) <0.0001
aCDI incidence calculated at CDI discharges per 1000 total discharges
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Several factors could contribute to the disparate CDI
incidence increase and health outcomes among the
elderly compared to other age groups. Advanced pa-
tient age has been previously linked to an increase risk
for CDI development. This is likely attributed to in-
nate and iatrogenic changes such as: immunosenes-
cence [17], higher prevalence of comorbid illness [18],
changes in the gut flora [17], more healthcare expo-
sures (e.g., hospitalizations and long-term care facility
residence), and exposure to antibiotics [19] and other
medications (e.g., proton pump inhibitors [PPIs]) [20].
In recent years, there has been an increase in the use
of certain antibiotics, particularly among the elderly.
Lee et al. [21] demonstrated an increase in overall anti-
biotic use in older adult patients by 30% and use of broad
spectrum antibiotics in elderly adults by 68% from 2000 to
2010. Furthermore, two meta-analyses suggest that PPI
use is associated with increased risk for CDI [22, 23].
Often, patients take PPIs inappropriately [24, 25].
Choudhry et al. [25] found that in a predominately elderly
population (median age 76 years), more than half (53.4%)
were prescribed a PPI without an appropriate indication.
Furthermore, 7.9% were prescribed a PPI for unknown
reasons. In addition, there has been a dramatic increase in
the use of PPIs among outpatients in the U.S. A 2013
study by Rotman et al. [24] found that the use of PPIs
more than doubled among outpatients in the U.S. between
2002 and 2009.
The poorer health outcomes among elderly patients
with CDI could be due to several factors. First, the Euro-
pean and North American CDI guidelines report age over
65 years as a marker of severity [26, 27]. Severity of infec-
tion has been previously linked with increased patient
mortality, as well as longer hospital LOS [28]. Addition-
ally, a prior study demonstrated an increased risk of severe
infection and death due to the more pathogenic C. difficile
strain, BI/NAP1/027 strain in elderly adults compared to
younger populations [29].
Our study findings are important for several reasons.
First, in 2001, elderly adults represented approximately
13% of the U.S. population. During our study period,
there was an addition of approximately five million eld-
erly adults to the U.S. population [30]. By the year 2030,
it is expected that elderly adults will grow to 19% of the
total U.S. population. As the population ages, a greater
proportion of Americans become high-risk for develop-
ing CDI. The incidence and health outcome trends elu-
cidated in our study may help increase awareness of
CDI, identify and protect high risk patients, and possibly
reduce the occurrence of CDI in the hospital setting.
Conclusions
CDI incidence was highest among elderly adults at
least 65 years of age, followed by adults and pediatric
patients. The increase in CDI incidence among the
elderly markedly outpaced that of the other two age
group populations from 2001 to 2010. Additionally,
elderly adults experienced higher all-cause, in-hospital
mortality and longer hospitals stays as compared to
adults and pediatrics patients.
Limitations
This study has potential limitations. First, this study was
retrospective and relied on administrative coding to identify
CDI cases rather than positive laboratory identification of
C. difficile, which could result in misclassification bias. Al-
though the use of ICD-9-CM codes to identify CDI has
relatively high specificity (99.7%) and sensitivity (78%), it
cannot be considered equivalent to medical chart review or
microbiological analysis [31]. Importantly, our CDI case
definition did not change over the study period; therefore,
any coding error would persist throughout the study years
and would have limited effects on CDI trends. Additionally,
an initial CDI episode could not be discriminated from a
recurrent CDI episode or readmission. Furthermore, there
are factors that could have contributed to differences in
Fig. 1 CDI incidence among hospitalized patients by age group in the United States from 2001 to 2010
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CDI incidence and outcomes between age groups that we
were not able to account for in our analyses including: anti-
biotic exposure, differences in CDI testing procedures,
severity of comorbid illness, and C. difficile strain/ribotype.
The exclusion of federal hospitals and long-term care hos-
pitals in the NHDS and the lack of data after 2010 poten-
tially limit the generalizability to those settings and may
underestimate the burden of CDI in the U.S., particularly in
recent years. Finally, the NHDS includes a large sample
size, resulting in high study power. This limits the utility of
p-values to establish differences among groups, as small
variations are likely to be statistically significant.
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